Multilayered neuroprotection by cannabinoids in neurodegenerative diseases

Abstract

Neurodegenerative diseases are a complex ensemble of ailments characterized by progressive neuronal deterioration and ultimate loss, resulting in drastic impairments of memory, cognition and other brain functions. These incapacitating conditions are challenging for the public health system worldwide, with unfortunately no real cure and lack of efficient drugs capable of delaying or reversing these diseases. In this context, the endocannabinoid system and exogenous cannabinoids represent an interesting field of research due to numerous studies highlighting the neuroprotective effect of cannabinoids from different sources, i.e., endogenous, phytocannabinoids, and synthetic cannabinoids. This review highlights the multilayered effects of cannabinoids and the endocannabinoid system to block the progression of neurodegeneration and minimize the deleterious effects of insults that affect the brain. We illustrate examples showing that the main effects of cannabinoids modulate different components of the brain response to these insults at the level of three major mechanisms involved in neurodegeneration: neuroinflammation, excitotoxicity, and oxidative stress.

Keywords

Neurodegenerative diseases / cannabinoids and endocannabinoid system / microglia and astrocytes / neuroinflammation / oxidative stress / excitotoxicity

References

[1] Prusiner SB. Neurodegenerative diseases. In: Asbury AK, McKhann GM, McDonald WI, Goadsby PJ, McArthur JC, editors. Diseases of the Nervous System: Clinical Neuroscience and Therapeutic Principles. Cambridge University Press; 2002. pp. 210-36.

[2] Ren S, Wang Z, Zhang Y, Chen N. Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors. Acta Pharmacol Sin. 2020; 41: 1263-71.

[3] Gao J, Wang L, Huntley ML, Perry G, Wang X. Pathomechanisms of TDP-43 in neurodegeneration. J Neurochem. 2018; [Epub ahead of print].

[4] Farooqui AA. Neurochemical Aspects of Neurological Disorders. In: Curcumin for Neurological and Psychiatric Disorders. Elsevier; 2019. pp. 1-22.

[5] Kasatkina LA, Rittchen S, Sturm EM. Neuroprotective and Immunomodulatory Action of the Endocannabinoid System under Neuroinflammation. Int J Mol Sci. 2021; 22: 5431.

[6] Gilgun-Sherki Y, Melamed E, Mechoulam R, Offen D. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacol Toxicol. 2003; 93: 66-70.

[7] Xu B, Li M, Chen K, Li X, Cai N, Xu J. Mitofusin-2 mediates cannabidiol-induced neuroprotection against cerebral ischemia in rats. Acta Pharmacol Sin. 2023; 44: 499-512.

[8] Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y). 2018; 4: 575-90.

[9] Shichiri M. The role of lipid peroxidation in neurological disorders. J Clin Biochem Nutr. 2014; 54: 151-60.

[10] Bhunia S, Kolishetti N, Arias AY, Vashist A, Nair M. Cannabidiol for neurodegenerative disorders: A comprehensive review. Front Pharmacol. 2022; 13: 989717.

[11] Salim S. Oxidative Stress and the Central Nervous System. J Pharmacol Exp Ther. 2017; 360: 201-5.

[12] Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010; 140: 918-34.

[13] Castelli V, d’Angelo M, Quintiliani M, Benedetti E, Cifone MG, Cimini A. The emerging role of probiotics in neurodegenerative diseases: new hope for Parkinson’s disease? Neural Regen Res. 2021; 16: 628-34.

[14] Basavarajappa BS, Shivakumar M, Joshi V, Subbanna S. Endocannabinoid system in neurodegenerative disorders. J Neurochem. 2017; 142: 624-48.

[15] McFarthing K, Rafaloff G, Baptista MAS, Wyse RK, Stott SRW. Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update. J Parkinsons Dis. 2021; 11: 891-903.

[16] Wang X, Zhang H, Liu Y, Xu Y, Yang B, Li H. An overview on synthetic and biological activities of cannabidiol (CBD) and its derivatives. Bioorg Chem. 2023; 140: 106810.

[17] Cassano T, Villani R, Pace L, Carbone A, Bukke VN, Orkisz S. From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases. Front Pharmacol. 2020; 11: 124.

[18] Smith S, Spurgeon T, Spurgeon R, Heal D. Phytocannabinoids-Evaluation of their therapeutic role in neuroinflammation. Explor Neuroprot Ther. 2024; 4: 325-48.

[19] Stone NL, Murphy AJ, England TJ, O’Sullivan SE. A systematic review of minor phytocannabinoids with promising neuroprotective potential. Br J Pharmacol. 2020; 177: 4330-52.

[20] Galve-Roperh I, Aguado T, Palazuelos J, Guzmán M. Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des. 2008; 14: 2279-88.

[21] Tadijan A, Vlašić I, Vlainić J, Đikić D, Oršolić N, Jembrek MJ. Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions. Antioxidants (Basel). 2022; 11: 2049.

[22] Fernández-Ruiz J, Moro MA, Martínez-Orgado J. Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. Neurotherapeutics. 2015; 12: 793-806.

[23] Pérez-Olives C, Rivas-Santisteban R, Lillo J, Navarro G, Franco R. Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer’s, Parkinson’s, and Huntington’s Diseases. In: Murillo-Rodriguez E, Pandi-Perumal SR, Monti JM, editors. Cannabinoids and Neuropsychiatric Disorders. Cham: Springer International Publishing; 2021. pp. 81-92.

[24] ElSohly MA, Chandra S, Radwan M, Majumdar CG, Church JC. A Comprehensive Review of Cannabis Potency in the United States in the Last Decade. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021; 6: 603-6.

[25] ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod. 2017; 103: 1-36.

[26] Gaoni Y, Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. J Am Chem Soc. 1964; 86: 1646-7.

[27] Adams R, Hunt M, Clark JH. Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. I. J Am Chem Soc. 1940; 62: 196-200.

[28] Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Marzo VD, Elphick MR. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂ . Pharmacol Rev. 2010; 62: 588-631.

[29] Caprioglio D, Amin HIM, Taglialatela-Scafati O, Muñoz E, Appendino G. Minor Phytocannabinoids: A Misleading Name but a Promising Opportunity for Biomedical Research. Biomolecules. 2022; 12: 1084.

[30] Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346: 561-4.

[31] Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993; 365: 61-5.

[32] Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006; 58: 389-462.

[33] Di Marzo V, Stella N, Zimmer A. Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci. 2015; 16: 30-42.

[34] Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992; 258: 1946-9.

[35] Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013; 64: 21-47.

[36] Lu H, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry. 2016; 79: 516-25.

[37] Szabo B, Siemes S, Wallmichrath I. Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur J Neurosci. 2002; 15: 2057-61.

[38] Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018; 19: 833.

[39] Sánchez-Blázquez P, Rodríguez-Muñoz M, Garzón J. The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Front Pharmacol. 2014; 4: 169.

[40] Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem. 2005; 95: 437-45.

[41] Komorowska-Müller JA, Rana T, Olabiyi BF, Zimmer A, Schmöle A. Cannabinoid Receptor 2 Alters Social Memory and Microglial Activity in an Age-Dependent Manner. Molecules. 2021; 26: 5984.

[42] Eraso-Pichot A, Pouvreau S, Olivera-Pinto A, Gomez-Sotres P, Skupio U, Marsicano G. Endocannabinoid signaling in astrocytes. Glia. 2023; 71: 44-59.

[43] Molina-Holgado F, Molina-Holgado E, Guaza C, Rothwell NJ. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J Neurosci Res. 2002; 67: 829-36.

[44] Freundt-Revilla J, Kegler K, Baumgärtner W, Tipold A. Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system. PLoS One. 2017; 12: e0181064.

[45] Hasbi A, Madras BK, George SR. Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review. Brain Sci. 2023; 13: 325.

[46] Sun Y, Alexander SPH, Garle MJ, Gibson CL, Hewitt K, Murphy SP. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol. 2007; 152: 734-43.

[47] Chávez AE, Chiu CQ, Castillo PE. TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nat Neurosci. 2010; 13: 1511-8.

[48] Ambrosino P, Soldovieri MV, Russo C, Taglialatela M. Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. Br J Pharmacol. 2013; 168: 1430-44.

[49] Pazos MR, Mohammed N, Lafuente H, Santos M, Martínez-Pinilla E, Moreno E. Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology. 2013; 71: 282-91.

[50] Lauckner JE, Jensen JB, Chen H, Lu H, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A. 2008; 105: 2699-704.

[51] Balenga NAB, Aflaki E, Kargl J, Platzer W, Schröder R, Blättermann S. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res. 2011; 21: 1452-69.

[52] Reyes-Resina I, Navarro G, Aguinaga D, Canela EI, Schoeder CT, Załuski M. Molecular and functional interaction between GPR18 and cannabinoid CB₂ G-protein-coupled receptors. Relevance in neurodegenerative diseases. Biochem Pharmacol. 2018; 157: 169-79.

[53] Rios C, Gomes I, Devi LA. mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol. 2006; 148: 387-95.

[54] Palazzos E, de Novellis V, Marabese I, Rossi F, Maione S. Metabotropic glutamate and cannabinoid receptor crosstalk in periaqueductal grey pain processing. Curr Neuropharmacol. 2006; 4: 225-31.

[55] Sylantyev S, Jensen TP, Ross RA, Rusakov DA. Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci U S A. 2013; 110: 5193-8.

[56] Muller C, Morales P, Reggio PH. Cannabinoid Ligands Targeting TRP Channels. Front Mol Neurosci. 2019; 11: 487.

[57] Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995; 50: 83-90.

[58] Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995; 215: 89-97.

[59] Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A. 2001; 98: 3662-5.

[60] Porter AC, Sauer J, Knierman MD, Becker GW, Berna MJ, Bao J. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther. 2002; 301: 1020-4.

[61] Leggett JD, Aspley S, Beckett SRG, D’Antona AM, Kendall DA, Kendall DA. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol. 2004; 141: 253-62.

[62] Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci U S A. 1993; 90: 7656-60.

[63] Woodward DF, Carling RWC, Cornell CL, Fliri HG, Martos JL, Pettit SN. The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol Ther. 2008; 120: 71-80.

[64] van der Stelt M, van Kuik JA, Bari M, van Zadelhoff G, Leeflang BR, Veldink GA. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. J Med Chem. 2002; 45: 3709-20.

[65] Fowler CJ. Anandamide uptake explained? Trends Pharmacol Sci. 2012; 33: 181-5.

[66] Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 2001; 410: 588-92.

[67] Navarrete M, Araque A. Endocannabinoids Mediate Neuron-Astrocyte Communication. Neuron. 2008; 57: 883-93.

[68] Araque A, Castillo PE, Manzoni OJ, Tonini R. Synaptic functions of endocannabinoid signaling in health and disease. Neuropharmacology. 2017; 124: 13-24.

[69] Skaper SD, Di Marzo V. Endocannabinoids in nervous system health and disease: the big picture in a nutshell. Philos Trans R Soc Lond B Biol Sci. 2012; 367: 3193-200.

[70] Martínez-Pinilla E, Reyes-Resina I, Oñatibia-Astibia A, Zamarbide M, Ricobaraza A, Navarro G. CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum. Exp Neurol. 2014; 261: 44-52.

[71] Chagas MHN, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol. 2014; 28: 1088-98.

[72] Baul HS, Manikandan C, Sen D. Cannabinoid receptor as a potential therapeutic target for Parkinson’s Disease. Brain Res Bull. 2019; 146: 244-52.

[73] Burgaz S, García C, Gómez-Cañas M, Muñoz E, Fernández-Ruiz J. Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease. Molecules. 2019; 24: 2702.

[74] Burgaz S, García C, Gómez-Cañas M, Navarrete C, García-Martín A, Rolland A. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson’s disease using 6-hydroxydopamine-lesioned mice. Mol Cell Neurosci. 2021; 110: 103583.

[75] Del-Bel E, Barros-Pereira N, de Moraes RP, de Mattos BA, Alves-Fernandes TA, de Abreu LB. A journey through cannabidiol in Parkinson’s disease. Int Rev Neurobiol. 2024; 177: 65-93.

[76] García-Arencibia M, García C, Fernández-Ruiz J. Cannabinoids and Parkinson’s disease. CNS Neurol Disord Drug Targets. 2009; 8: 432-9.

[77] Cerri S, Levandis G, Ambrosi G, Montepeloso E, Antoninetti GF, Franco R. Neuroprotective Potential of Adenosine A2A and Cannabinoid CB1 Receptor Antagonists in an Animal Model of Parkinson Disease. J Neuropathol Exp Neurol. 2014; 73: 414-24.

[78] Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol-recent advances. Chem Biodivers. 2007; 4: 1678-92.

[79] Crippa JAS, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Dos Santos RG. Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms? Eur Arch Psychiatry Clin Neurosci. 2019; 269: 121-33.

[80] Ferreira-Junior NC, Campos AC, Guimarães FS, Del-Bel E, Zimmermann PMDR, Brum Junior L. Biological bases for a possible effect of cannabidiol in Parkinson’s disease. Braz J Psychiatry. 2020; 42: 218-24.

[81] Ramírez BG, Blázquez C, del Pulgar TG, Guzmán M, de Ceballos ML. Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005; 25: 1904-13.

[82] Rapino C, Tortolani D, Scipioni L, Maccarrone M. Neuroprotection by (endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases. Curr Neuropharmacol. 2018; 16: 959-70.

[83] Casarejos MJ, Perucho J, Gomez A, Muñoz MP, Fernandez-Estevez M, Sagredo O. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis. 2013; 35: 525-39.

[84] Xiang X, Wang X, Wu Y, Hu J, Li Y, Jin S. Activation of GPR55 attenuates cognitive impairment, oxidative stress, neuroinflammation, and synaptic dysfunction in a streptozotocin-induced Alzheimer’s mouse model. Pharmacol Biochem Behav. 2022; 214: 173340.

[85] Sagredo O, García-Arencibia M, de Lago E, Finetti S, Decio A, Fernández-Ruiz J. Cannabinoids and neuroprotection in basal ganglia disorders. Mol Neurobiol. 2007; 36: 82-91.

[86] Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis. 2006; 22: 257-64.

[87] Ahmad A, Crupi R, Impellizzeri D, Campolo M, Marino A, Esposito E. Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice. Brain Behav Immun. 2012; 26: 1310-21.

[88] Amenta PS, Jallo JI, Tuma RF, Hooper DC, Elliott MB. Cannabinoid receptor type-2 stimulation, blockade, and deletion alter the vascular inflammatory responses to traumatic brain injury. J Neuroinflammation. 2014; 11: 191.

[89] Amenta PS, Jallo JI, Tuma RF, Elliott MB. A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury. J Neurosci Res. 2012; 90: 2293-305.

[90] Bietar B, Tanner S, Lehmann C. Neuroprotection and Beyond: The Central Role of CB1 and CB2 Receptors in Stroke Recovery. Int J Mol Sci. 2023; 24: 16728.

[91] Carter C, Laviolette L, Bietar B, Zhou J, Lehmann C. Cannabis, Cannabinoids, and Stroke: Increased Risk or Potential for Protection-A Narrative Review. Curr Issues Mol Biol. 2024; 46: 3122-33.

[92] Zhuang Q, Dai C, Yang L, Wen H, Wang H, Jiang X. Stimulated CB1 Cannabinoid Receptor Inducing Ischemic Tolerance and Protecting Neuron from Cerebral Ischemia. Cent Nerv Syst Agents Med Chem. 2017; 17: 141-50.

[93] Biegon A. Cannabinoids as neuroprotective agents in traumatic brain injury. Curr Pharm Des. 2004; 10: 2177-83.

[94] Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol. 1997; 72: 169-77.

[95] Zhang M, Adler MW, Abood ME, Ganea D, Jallo J, Tuma RF. CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvasc Res. 2009; 78: 86-94.

[96] Lopez-Rodriguez AB, Siopi E, Finn DP, Marchand-Leroux C, Garcia-Segura LM, Jafarian-Tehrani M. CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice. Cereb Cortex. 2015; 25: 35-45.

[97] Meyer E, Bonato JM, Mori MA, Mattos BA, Guimarães FS, Milani H. Cannabidiol Confers Neuroprotection in Rats in a Model of Transient Global Cerebral Ischemia: Impact of Hippocampal Synaptic Neuroplasticity. Mol Neurobiol. 2021; 58: 5338-55.

[98] Bilsland LG, Greensmith L. The endocannabinoid system in amyotrophic lateral sclerosis. Curr Pharm Des. 2008; 14: 2306-16.

[99] Docagne F, Muñetón V, Clemente D, Ali C, Loría F, Correa F. Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Mol Cell Neurosci. 2007; 34: 551-61.

[100] Docagne F, Mestre L, Loría F, Hernangómez M, Correa F, Guaza C. Therapeutic potential of CB2 targeting in multiple sclerosis. Expert Opin Ther Targets. 2008; 12: 185-95.

[101] Correa F, Mestre L, Molina-Holgado E, Arévalo-Martín A, Docagne F, Romero E. The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation. Mini Rev Med Chem. 2005; 5: 671-5.

[102] Bisogno T, Martire A, Petrosino S, Popoli P, Di Marzo V. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington’s disease. Neurochem Int. 2008; 52: 307-13.

[103] Aguareles J, Paraíso-Luna J, Palomares B, Bajo-Grañeras R, Navarrete C, Ruiz-Calvo A. Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration. Transl Neurodegener. 2019; 8: 9.

[104] Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O. Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics. 2015; 12: 185-99.

[105] Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J. Cannabinoids: novel medicines for the treatment of Huntington’s disease. Recent Pat CNS Drug Discov. 2012; 7: 41-8.

[106] Panahi Y, Manayi A, Nikan M, Vazirian M. The arguments for and against cannabinoids application in glaucomatous retinopathy. Biomed Pharmacother. 2017; 86: 620-7.

[107] Nucci C, Bari M, Spanò A, Corasaniti M, Bagetta G, Maccarrone M. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. Prog Brain Res. 2008; 173: 451-64.

[108] Bucolo C, Platania CBM, Drago F, Bonfiglio V, Reibaldi M, Avitabile T. Novel Therapeutics in Glaucoma Management. Curr Neuropharmacol. 2018; 16: 978-92.

[109] El-Remessy AB, Khalil IE, Matragoon S, Abou-Mohamed G, Tsai N, Roon P. Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am J Pathol. 2003; 163: 1997-2008.

[110] Lax P, Esquiva G, Altavilla C, Cuenca N. Neuroprotective effects of the cannabinoid agonist HU210 on retinal degeneration. Exp Eye Res. 2014; 120: 175-85.

[111] Jordan E, Nguyen G, Piechot A, Kayser O. Cannabinoids as New Drug Candidates for the Treatment of Glaucoma. Planta Med. 2022; 88: 1267-74.

[112] Naveh N, Weissman C, Muchtar S, Benita S, Mechoulam R. A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits. Graefes Arch Clin Exp Ophthalmol. 2000; 238: 334-8.

[113] Rosenberg EC, Patra PH, Whalley BJ. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy Behav. 2017; 70: 319-27.

[114] Libro R, Giacoppo S, Rajan TS, Bramanti P, Mazzon E. Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview. Molecules. 2016; 21: 518.

[115] Colizzi M, Bortoletto R, Costa R, Zoccante L. Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence. Nutrients. 2021; 13: 1346.

[116] Kidd VD. Cannabinoids in the Treatment of Autism Spectrum Disorder: Demanding Data Before Using Fad Therapies. Pediatr Neurol. 2018; 88: 10-1.

[117] Costa AC, Joaquim HPG, Pedrazzi JFC, de O Pain A, Duque G, Aprahamian I. Cannabinoids in Late Life Parkinson’s Disease and Dementia: Biological Pathways and Clinical Challenges. Brain Sci. 2022; 12: 1596.

[118] Li H, Liu Y, Tian D, Tian L, Ju X, Qi L. Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer’s disease. Eur J Med Chem. 2020; 192: 112163.

[119] Cernak I, Vink R, Natale J, Stoica B, Lea PM 4th, Movsesyan V. The “dark side” of endocannabinoids: a neurotoxic role for anandamide. J Cereb Blood Flow Metab. 2004; 24: 564-78.

[120] Sarne Y, Asaf F, Fishbein M, Gafni M, Keren O. The dual neuroprotective-neurotoxic profile of cannabinoid drugs. Br J Pharmacol. 2011; 163: 1391-401.

[121] Sarne Y, Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord. 2005; 4: 677-84.

[122] Sarne Y. Beneficial and deleterious effects of cannabinoids in the brain: the case of ultra-low dose THC. Am J Drug Alcohol Abuse. 2019; 45: 551-62.

[123] Pope C, Mechoulam R, Parsons L. Endocannabinoid signaling in neurotoxicity and neuroprotection. Neurotoxicology. 2010; 31: 562-71.

[124] Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004; 3: 771-84.

[125] Kim SH, Won SJ, Mao XO, Jin K, Greenberg DA. Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. Mol Pharmacol. 2006; 69: 691-6.

[126] Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants (Basel). 2019; 9: 21.

[127] Fischer R, Maier O. Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxid Med Cell Longev. 2015; 2015: 610813.

[128] Chen X, Guo C, Kong J. Oxidative stress in neurodegenerative diseases. Neural Regen Res. 2012; 7: 376-85.

[129] Adamu A, Li S, Gao F, Xue G. The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets. Front Aging Neurosci. 2024; 16: 1347987.

[130] Mishra A, Bandopadhyay R, Singh PK, Mishra PS, Sharma N, Khurana N. Neuroinflammation in neurological disorders: pharmacotherapeutic targets from bench to bedside. Metab Brain Dis. 2021; 36: 1591-626.

[131] Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci. 2010; 11: 682-96.

[132] Zhou X, Hollern D, Liao J, Andrechek E, Wang H. NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors. Cell Death Dis. 2013; 4: e560.

[133] Stella N, Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol. 2001; 425: 189-96.

[134] Varma N, Carlson GC, Ledent C, Alger BE. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J Neurosci. 2001; 21: RC188.

[135] Mecha M, Feliú A, Carrillo-Salinas FJ, Rueda-Zubiaurre A, Ortega-Gutiérrez S, de Sola RG. Endocannabinoids drive the acquisition of an alternative phenotype in microglia. Brain Behav Immun. 2015; 49: 233-45.

[136] Al-Khazaleh AK, Zhou X, Bhuyan DJ, Münch GW, Al-Dalabeeh EA, Jaye K. The Neurotherapeutic Arsenal in Cannabis sativa: Insights into Anti-Neuroinflammatory and Neuroprotective Activity and Potential Entourage Effects. Molecules. 2024; 29: 410.

[137] Hickman S, Izzy S, Sen P, Morsett L, Khoury JE. Microglia in neurodegeneration. Nat Neurosci. 2018; 21: 1359-69.

[138] Hosseini AM, Majidi J, Baradaran B, Yousefi M. Toll-Like Receptors in the Pathogenesis of Autoimmune Diseases. Adv Pharm Bull. 2015; 5: 605-14.

[139] García-Cáceres C, Balland E, Prevot V, Luquet S, Woods SC, Koch M. Role of astrocytes, microglia, and tanycytes in brain control of systemic metabolism. Nat Neurosci. 2019; 22: 7-14.

[140] Young AP, Denovan-Wright EM. The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation. Front Pharmacol. 2022; 12: 806417.

[141] Tanaka M, Sackett S, Zhang Y. Endocannabinoid Modulation of Microglial Phenotypes in Neuropathology. Front Neurol. 2020; 11: 87.

[142] Kreutz S, Koch M, Böttger C, Ghadban C, Korf H, Dehghani F. 2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells. Glia. 2009; 57: 286-94.

[143] Zhang L, Zhou Y, Yu Z, Zhang X, Shi J, Shen H. Restoring glutamate homeostasis in the nucleus accumbens via endocannabinoid-mimetic drug prevents relapse to cocaine seeking behavior in rats. Neuropsychopharmacology. 2021; 46: 970-81.

[144] Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci. 2003; 23: 1398-405.

[145] Walter L, Franklin A, Witting A, Moller T, Stella N. Astrocytes in culture produce anandamide and other acylethanolamides. J Biol Chem. 2002; 277: 20869-76.

[146] Hegyi Z, Oláh T, Kőszeghy Á, Piscitelli F, Holló K, Pál B. CB₁ receptor activation induces intracellular Ca²⁺ mobilization and 2-arachidonoylglycerol release in rodent spinal cord astrocytes. Sci Rep. 2018; 8: 10562.

[147] Panikashvili D, Simeonidou C, Ben-Shabat S, Hanuš L, Breuer A, Mechoulam R. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 2001; 413: 527-31.

[148] Kokona D, Spyridakos D, Tzatzarakis M, Papadogkonaki S, Filidou E, Arvanitidis KI. The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity. Neuropharmacology. 2021; 185: 108450.

[149] Viader A, Blankman JL, Zhong P, Liu X, Schlosburg JE, Joslyn CM. Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action. Cell Rep. 2015; 12: 798-808.

[150] Beggiato S, Cassano T, Ferraro L, Tomasini MC. Astrocytic palmitoylethanolamide pre-exposure exerts neuroprotective effects in astrocyte-neuron co-cultures from a triple transgenic mouse model of Alzheimer’s disease. Life Sci. 2020; 257: 118037.

[151] Phatnani HP, Guarnieri P, Friedman BA, Carrasco MA, Muratet M, O’Keeffe S. Intricate interplay between astrocytes and motor neurons in ALS. Proc Natl Acad Sci U S A. 2013; 110: E756-65.

[152] Beggiato S, Borelli AC, Ferraro L, Tanganelli S, Antonelli T, Tomasini MC. Palmitoylethanolamide Blunts Amyloid-β42-Induced Astrocyte Activation and Improves Neuronal Survival in Primary Mouse Cortical Astrocyte-Neuron Co-Cultures. J Alzheimers Dis. 2018; 61: 389-99.

[153] Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L Jr. Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide. J Cell Mol Med. 2011; 15: 2664-74.

[154] Gajardo-Gómez R, Labra VC, Maturana CJ, Shoji KF, Santibañez CA, Sáez JC. Cannabinoids prevent the amyloid β-induced activation of astroglial hemichannels: A neuroprotective mechanism. Glia. 2017; 65: 122-37.

[155] Ranieri R, Laezza C, Bifulco M, Marasco D, Malfitano AM. Endocannabinoid System in Neurological Disorders. Recent Pat CNS Drug Discov. 2016; 10: 90-112.

[156] Thapa S, Singh SK. The Role of Endocannabinoid System in Neuroprotection: Molecular Targets and Therapeutic Opportunities. Integr Med Rep. 2023; 2: 72-86.

[157] Murphy N, Cowley TR, Blau CW, Dempsey CN, Noonan J, Gowran A. The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation. J Neuroinflammation. 2012; 9: 79.

[158] Piro JR, Suidan GL, Quan J, Pi Y, O’Neill SM, Ilardi M. Inhibition of 2-AG hydrolysis differentially regulates blood brain barrier permeability after injury. J Neuroinflammation. 2018; 15: 142.

[159] Orefice NS, Alhouayek M, Carotenuto A, Montella S, Barbato F, Comelli A. Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics. 2016; 13: 428-38.

[160] Siracusa R, Paterniti I, Impellizzeri D, Cordaro M, Crupi R, Navarra M. The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson’s Disease Model. CNS Neurol Disord Drug Targets. 2015; 14: 1350-65.

[161] Crupi R, Impellizzeri D, Cordaro M, Siracusa R, Casili G, Evangelista M. N-palmitoylethanolamide Prevents Parkinsonian Phenotypes in Aged Mice. Mol Neurobiol. 2018; 55: 8455-72.

[162] Paterniti I, Impellizzeri D, Crupi R, Morabito R, Campolo M, Esposito E. Molecular evidence for the involvement of PPAR-δ and PPAR-γ in anti-inflammatory and neuroprotective activities of palmitoylethanolamide after spinal cord trauma. J Neuroinflammation. 2013; 10: 20.

[163] Cordaro M, Impellizzeri D, Paterniti I, Bruschetta G, Siracusa R, Stefano DD. Neuroprotective Effects of Co-UltraPEALut on Secondary Inflammatory Process and Autophagy Involved in Traumatic Brain Injury. J Neurotrauma. 2016; 33: 132-46.

[164] Impellizzeri D, Cordaro M, Bruschetta G, Siracusa R, Crupi R, Esposito E. N-Palmitoylethanolamine-Oxazoline as a New Therapeutic Strategy to Control Neuroinflammation: Neuroprotective Effects in Experimental Models of Spinal Cord and Brain Injury. J Neurotrauma. 2017; 34: 2609-23.

[165] Javed H, Azimullah S, Haque ME, Ojha SK. Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson’s Disease. Front Neurosci. 2016; 10: 321.

[166] Li L, Tao Y, Tang J, Chen Q, Yang Y, Feng Z. A Cannabinoid Receptor 2 Agonist Prevents Thrombin-Induced Blood-Brain Barrier Damage via the Inhibition of Microglial Activation and Matrix Metalloproteinase Expression in Rats. Transl Stroke Res. 2015; 6: 467-77.

[167] Sahu P, Mudgal J, Arora D, Kinra M, Mallik SB, Rao CM. Cannabinoid receptor 2 activation mitigates lipopolysaccharide-induced neuroinflammation and sickness behavior in mice. Psychopharmacology (Berl). 2019; 236: 1829-38.

[168] Roche M, Diamond M, Kelly JP, Finn DP. In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids. J Neuroimmunol. 2006; 181: 57-67.

[169] Lou Z, Zhao C, Xiao B. Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist. J Neurosci Res. 2012; 90: 84-95.

[170] Kasatkina LA, Heinemann A, Hudz YA, Thomas D, Sturm EM. Stearoylethanolamide interferes with retrograde endocannabinoid signalling and supports the blood-brain barrier integrity under acute systemic inflammation. Biochem Pharmacol. 2020; 174: 113783.

[171] Hind WH, Tufarelli C, Neophytou M, Anderson SI, England TJ, O’Sullivan SE. Endocannabinoids modulate human blood-brain barrier permeability in vitro. Br J Pharmacol. 2015; 172: 3015-27.

[172] Rathod SS, Agrawal YO. Phytocannabinoids as Potential Multitargeting Neuroprotectants in Alzheimer’s Disease. Curr Drug Res Rev. 2024; 16: 94-110.

[173] Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017; 175: 133-50.

[174] Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Front Immunol. 2018; 9: 2009.

[175] Jiang H, Li H, Cao Y, Zhang R, Zhou L, Zhou Y. Effects of cannabinoid (CBD) on blood brain barrier permeability after brain injury in rats. Brain Res. 2021; 1768: 147586.

[176] Mannucci C, Navarra M, Calapai F, Spagnolo EV, Busardò FP, Cas RD. Neurological Aspects of Medical Use of Cannabidiol. CNS Neurol Disord Drug Targets. 2017; 16: 541-53.

[177] Vendel E, de Lange ECM. Functions of the CB1 and CB2 receptors in neuroprotection at the level of the blood-brain barrier. Neuromolecular Med. 2014; 16: 620-42.

[178] Chung YC, Shin W, Baek JY, Cho EJ, Baik HH, Kim SR. CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson’s disease. Exp Mol Med. 2016; 48: e205.

[179] Zhang M, Martin BR, Adler MW, Razdan RK, Ganea D, Tuma RF. Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience. 2008; 152: 753-60.

[180] Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther. 2023; 8: 267.

[181] Aso E, Ferrer I. CB2 Cannabinoid Receptor As Potential Target against Alzheimer’s Disease. Front Neurosci. 2016; 10: 243.

[182] Fujii M, Sherchan P, Krafft PR, Rolland WB, Soejima Y, Zhang JH. Cannabinoid type 2 receptor stimulation attenuates brain edema by reducing cerebral leukocyte infiltration following subarachnoid hemorrhage in rats. J Neurol Sci. 2014; 342: 101-6.

[183] Benito C, Núñez E, Tolón RM, Carrier EJ, Rábano A, Hillard CJ. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains. J Neurosci. 2003; 23: 11136-41.

[184] Benito C, Tolón RM, Pazos MR, Núñez E, Castillo AI, Romero J. Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol. 2008; 153: 277-85.

[185] Onaivi ES, Ishiguro H, Gong J, Patel S, Meozzi PA, Myers L. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One. 2008; 3: e1640.

[186] Tolón RM, Núñez E, Pazos MR, Benito C, Castillo AI, Martínez-Orgado JA. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res. 2009; 1283: 148-54.

[187] Ashton JC, Glass M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol. 2007; 5: 73-80.

[188] Bie B, Wu J, Foss JF, Naguib M. An overview of the cannabinoid type 2 receptor system and its therapeutic potential. Curr Opin Anaesthesiol. 2018; 31: 407-14.

[189] Gado F, Digiacomo M, Macchia M, Bertini S, Manera C. Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis. Medicines. 2018; 5: 91.

[190] Gado F, Di Cesare Mannelli L, Lucarini E, Bertini S, Cappelli E, Digiacomo M. Identification of the First Synthetic Allosteric Modulator of the CB₂ Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief. J Med Chem. 2019; 62: 276-87.

[191] Morris GP, Clark IA, Vissel B. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer’s disease. Acta Neuropathol Commun. 2014; 2: 135.

[192] Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR, Jones RW. Drug development in Alzheimer’s disease: the path to 2025. Alz Res Therapy. 2016; 8: 39.

[193] Fagan SG, Campbell VA. The influence of cannabinoids on generic traits of neurodegeneration. Br J Pharmacol. 2014; 171: 1347-60.

[194] Boyd RJ, Avramopoulos D, Jantzie LL, McCallion AS. Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases. J Neuroinflammation. 2022; 19: 223.

[195] Bohlen CJ, Friedman BA, Dejanovic B, Sheng M. Microglia in Brain Development, Homeostasis, and Neurodegeneration. Annu Rev Genet. 2019; 53: 263-88.

[196] Dash UC, Bhol NK, Swain SK, Samal RR, Nayak PK, Raina V. Oxidative stress and inflammation in the pathogenesis of neurological disorders: Mechanisms and implications. Acta Pharm Sin B. 2024;S2211383524004040.

[197] Borsche M, Pereira SL, Klein C, Grünewald A. Mitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects. J Parkinsons Dis. 2021; 11: 45-60.

[198] Mulica P, Grünewald A, Pereira SL. Astrocyte-Neuron Metabolic Crosstalk in Neurodegeneration: A Mitochondrial Perspective. Front Endocrinol (Lausanne). 2021; 12: 668517.

[199] Yan X, Wang B, Hu Y, Wang S, Zhang X. Abnormal Mitochondrial Quality Control in Neurodegenerative Diseases. Front Cell Neurosci. 2020; 14: 138.

[200] Wang L, Yang Z, He X, Pu S, Yang C, Wu Q. Mitochondrial protein dysfunction in pathogenesis of neurological diseases. Front Mol Neurosci. 2022; 15: 974480.

[201] Simpson DSA, Oliver PL. ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease. Antioxidants (Basel). 2020; 9: 743.

[202] Sakellariou GK, Pearson T, Lightfoot AP, Nye GA, Wells N, Giakoumaki II. Long-term administration of the mitochondria-targeted antioxidant mitoquinone mesylate fails to attenuate age-related oxidative damage or rescue the loss of muscle mass and function associated with aging of skeletal muscle. FASEB J. 2016; 30: 3771-85.

[203] Fiebiger SM, Bros H, Grobosch T, Janssen A, Chanvillard C, Paul F. The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse. J Neuroimmunol. 2013; 262: 66-71.

[204] Aguilera-Portillo G, Rangel-López E, Villeda-Hernández J, Chavarría A, Castellanos P, Elmazoglu Z. The Pharmacological Inhibition of Fatty Acid Amide Hydrolase Prevents Excitotoxic Damage in the Rat Striatum: Possible Involvement of CB1 Receptors Regulation. Mol Neurobiol. 2019; 56: 844-56.

[205] Choi I, Ju C, Jalin AMAA, Lee DI, Prather PL, Kim W. Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury. Am J Pathol. 2013; 182: 928-39.

[206] Fraguas-Sánchez AI, Torres-Suárez AI. Medical Use of Cannabinoids. Drugs. 2018; 78: 1665-703.

[207] Valeri A, Mazzon E. Cannabinoids and Neurogenesis: The Promised Solution for Neurodegeneration? Molecules. 2021; 26: 6313.

[208] Bologov A, Gafni M, Keren O, Sarne Y. Dual neuroprotective and neurotoxic effects of cannabinoid drugs in vitro. Cell Mol Neurobiol. 2011; 31: 195-202.

[209] Fowler CJ, Rojo ML, Rodriguez-Gaztelumendi A. Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? Exp Neurol. 2010; 224: 37-47.

[210] Franco R, Morales P, Navarro G, Jagerovic N, Reyes-Resina I. The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CB₂ Receptors. Front Pharmacol. 2022; 13: 852631.

[211] Navarro G, Gómez-Autet M, Morales P, Rebassa JB, Torrent CLD, Jagerovic N. Homodimerization of CB₂ cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling. Pharmacol Res. 2024; 208: 107363.